Mode of action : antidepressive, anxiolytic
Spitomin is an anxiolytic, tranquilizer of non-benzodiazepine group, also has antidepressive effects.
In contrast to classical anxiolytics Spitomin has no antiepileptic, sedative, hypnotic and muscle relaxant effects.
The mechanism of action of Spitomin is associated with the effect of buspirone on the serotonergic and dopaminergic systems. Buspirone selectively blocking presynaptic dopamine receptors and increases the rate of excitation of the midbrain dopamine neurons. In addition, buspirone is partial selective agonist of 5-HT1A serotonin receptors. Buspirone has no significant effect on the benzodiazepine receptors and does not affect the binding of GABA, has no adverse effects on psychomotor functions, it does not cause tolerance, dependence and drug withdrawal. It does not potentiate the effect of alcohol. By anxiolytic activity of buspirone is approximately equal to the benzodiazepines.
The therapeutic effect develops gradually and is manifested in 7-14 days from the beginning of treatment, the maximum effect is registered after 4 weeks.
Indications :
generalized anxiety disorder (GAD);
panic disorder;
autonomic dysfunction syndrome;
alcohol
withdrawal syndrome (as adjuvant therapy);
depressive disorder - adjuvant therapy (Spitomin is not indicated for the monotherapy of depression).
